Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...

Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and ...

BCMA CAR T approvals (ide-cel 2021; cilta-cel 2022) deliver near-98% response in trials but require specialized centers, creating logistical constraints on access. Across >9 million UC patients, ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

A research team led by Albert Einstein College of Medicine scientists has developed a new strategy to engineer immune cells ...

Researchers in upstate New York are hopeful the work they’re doing may soon lead to new therapies for more cancer ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

The National Institute for Health and Care Excellence (NICE) has approved a chimeric antigen receptor (CAR) T-cell therapy for adults with large B-cell lymphoma. The treatment significantly delays ...